TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

CuraSen Therapeutics Secures Strategic Funding from the Alzheimer's Drug Discovery Foundation to Progress CST-3056, an Alpha-1A Adrenoceptor Agonist, in the Treatment of Alzheimer's Disease

Tuesday, October 10, 2023

CuraSen Therapeutics, a clinical-stage company focused on developing small molecule therapies for neurodegenerative diseases, has announced a significant investment of up to $5.8 million from the Alzheimer's Drug Discovery Foundation (ADDF) to advance CST-3056, an alpha-1A adrenoceptor (α1A-AR) agonist, as a potential treatment for Alzheimer's disease.

Anthony Ford, PhD, Chief Executive Officer of CuraSen Therapeutics, expressed excitement about the funding, stating that it will support the development of CST-3056 from preclinical stages to Phase 1 clinical trials. In addition to CST-3056, CuraSen Therapeutics is actively pursuing two other Phase 2 clinical-stage programs, CST-2032 and CST-103, to address neurodegenerative diseases, with the aim of providing vital treatment options for patients and caregivers.

CST-3056 targets alpha-1A adrenoceptors, known for their role in regulating neurotransmission and their prevalence in brain regions crucial for memory and learning. This makes them a promising target for Alzheimer's drug development, offering potential neuroprotective benefits. Dr. Howard Fillit, co-founder and Chief Science Officer of the Alzheimer's Drug Discovery Foundation, emphasized the importance of innovative approaches like the one pursued by CuraSen Therapeutics in advancing Alzheimer's therapeutics. This approach involves combining therapies and applying precision medicine to move closer to effective Alzheimer's treatments.

CuraSen Therapeutics plans to begin non-clinical studies in early 2024 and anticipates initiating Phase 1 clinical trials later in the same year.

Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to accelerating the discovery of drugs for preventing, treating, and ultimately curing Alzheimer's disease. The ADDF operates as a public charity with a focused mission of funding drug development for Alzheimer's. Using a venture philanthropy model, the ADDF supports research conducted in academia and the biotech industry. The ADDF has made significant contributions to the field, including supporting the development of the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®). Through generous donations, the ADDF has awarded over $270 million to fund more than 730 Alzheimer's drug discovery programs, biomarker initiatives, and clinical trials across 19 countries.

Alzheimer's disease is a progressive neurodegenerative condition and the leading cause of dementia. Approximately 50 million people worldwide are living with dementia. In its early stages, Alzheimer's is characterized by short-term memory loss. As the disease advances, patients experience increasingly noticeable and severe cognitive and functional impairments. Different forms of dementia may present with varying symptoms, including personality changes, language difficulties, and a loss of inhibitions.

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit